BMC cancer, 2024-01, Vol.24 (1), p.72-72, Article 72
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
- Ist Teil von
- BMC cancer, 2024-01, Vol.24 (1), p.72-72, Article 72
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2024
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Radiotherapy (RT) is an effective and available local treatment for patients with refractory or relapsed (R/R) aggressive B-cell lymphomas. However, the value of hypofractionated RT in this setting has not been confirmed. We retrospectively analyzed patients with R/R aggressive B-cell lymphoma who received hypofractionated RT between January 2020 and August 2022 at a single institution. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and acute side effects were analyzed. A total of 30 patients were included. The median dose for residual disease was 36 Gy, at a dose per fraction of 2.3-5 Gy. After RT, the ORR and complete response (CR) rates were 90% and 80%, respectively. With a median follow-up of 10 months (range, 2-27 months), 10 patients (33.3%) experienced disease progression and three died. The 1-year OS and PFS rates for all patients were 81.8% and 66.3%, respectively. The majority (8/10) of post-RT progressions involved out-of-field relapses. Patients with relapsed diseases, no response to systemic therapy, multiple lesions at the time of RT, and no response to RT were associated with out-of-field relapses. PFS was associated with response to RT (P = 0.001) and numbers of residual sites (P < 0.001). No serious non-hematological adverse effects (≥ grade 3) associated with RT were reported. These data suggest that hypofractionated RT was effective and tolerable for patients with R/R aggressive B-cell lymphoma, especially for those that exhibited localized residual disease.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1471-2407eISSN: 1471-2407DOI: 10.1186/s12885-024-11837-2Titel-ID: cdi_doaj_primary_oai_doaj_org_article_1c835e0171144cb98d6b06bc42b8a231
- Format
- –
- Schlagworte
- Antimitotic agents, Antineoplastic agents, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, B-cell lymphoma, Biopsy, Care and treatment, Chemotherapy, Diagnosis, Disease, Dosage and administration, Humans, Hypofractionated, Lymphatic system, Lymphocytes B, Lymphoma, Lymphoma, B-Cell - drug therapy, Lymphoma, B-Cell - radiotherapy, Lymphoma, Large B-Cell, Diffuse - drug therapy, Medical prognosis, Neoplasm Recurrence, Local - drug therapy, Neoplasm Recurrence, Local - radiotherapy, Non-Hodgkin's lymphomas, Patient outcomes, Patients, Radiation therapy, Radiotherapy, Recurrence, Refractory, Relapsed, Retrospective Studies, Rituximab, Rituximab - therapeutic use, Standard of care, Stem cells, Toxicity, Transplantation, Treatment Outcome